Cholinesterase Inhibitors in Heart Failure: Considerations and Precautions

Monitoring and Patient Selection

• The American College of Cardiology recommends careful cardiac monitoring, including signs of worsening heart failure symptoms, when initiating cholinesterase inhibitors in heart failure patients 1
• The European Society of Cardiology suggests avoiding or using cholinesterase inhibitors with extreme caution in patients with severe heart failure (NYHA class IV), recent heart failure exacerbation or hospitalization, or pre-existing heart block or bradycardia (heart rate < 60/min) 2

Dosing and Management of Adverse Effects

• The European Society of Cardiology recommends starting with the lowest possible dose and titrating very slowly with careful monitoring when using cholinesterase inhibitors in heart failure patients 2
• If bradycardia develops, the European Society of Cardiology suggests reducing dose or considering discontinuation, reviewing other heart rate-slowing medications, arranging ECG to exclude heart block, and seeking specialist advice 2